Intracellular Fatty Acid Levels Differentially Impact Target Silencing by FDA-approved siRNA Drugs
Published: 29 July 2025| Version 1 | DOI: 10.17632/r3h344p6r4.1
Contributor:
Sherouk TawfikDescription
This dataset contains raw and processed data from the investigation of how intracellular fatty acid accumulation impacts the efficacy of three FDA-approved siRNA drugs. Data are organized by experimental design, including cell type, FFA concentration, siRNA treatment, and measurements at both the mRNA and protein levels.
Files
Institutions
- University of ConnecticutCT, Storrs
Categories
Small Interfering RNA, Hepatic Steatosis